Stryker Corporation $SYK Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC cut its holdings in shares of Stryker Corporation (NYSE:SYK) by 4.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,310,122 shares of the medical technology company’s stock after selling 140,114 shares during the period. Fisher Asset Management LLC’s holdings in Stryker were worth $1,223,653,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Terra Alpha Investments LLC acquired a new stake in Stryker during the 3rd quarter worth about $1,216,000. Diversified Trust Co increased its position in shares of Stryker by 45.6% in the third quarter. Diversified Trust Co now owns 12,445 shares of the medical technology company’s stock worth $4,601,000 after acquiring an additional 3,899 shares in the last quarter. SVB Wealth LLC acquired a new stake in shares of Stryker during the second quarter valued at approximately $4,785,000. AXQ Capital LP purchased a new stake in shares of Stryker in the 2nd quarter valued at approximately $567,000. Finally, National Pension Service boosted its holdings in Stryker by 2.4% in the third quarter. National Pension Service now owns 683,867 shares of the medical technology company’s stock worth $252,805,000 after purchasing an additional 16,254 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Up 0.3%

Shares of SYK stock opened at $387.34 on Monday. The firm has a fifty day moving average of $363.17 and a 200-day moving average of $369.09. The stock has a market cap of $148.23 billion, a price-to-earnings ratio of 46.11, a P/E/G ratio of 2.26 and a beta of 0.87. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $404.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. The business had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.01 earnings per share. On average, equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is 41.90%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have weighed in on SYK shares. Piper Sandler reaffirmed an “overweight” rating on shares of Stryker in a research report on Tuesday, January 27th. TD Cowen lowered Stryker from a “buy” rating to a “hold” rating and set a $387.00 target price for the company. in a report on Monday, January 26th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $435.00 price objective on shares of Stryker in a report on Friday, November 14th. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Robert W. Baird set a $437.00 price objective on Stryker in a research report on Friday, January 30th. Thirteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $426.47.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.